Skip to main
NDRA
NDRA logo

NDRA Stock Forecast & Price Target

NDRA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ENDRA Life Sciences Inc. is focused on the innovative development of Thermo Acoustic Enhanced UltraSound (TAEUS), which aims to provide advanced tissue visualization and address the critical need for diagnostic tools in liver diseases affecting over one billion people globally. The company is anticipating FDA approval within the next year, which is expected to significantly influence the stock's valuation positively, as indicated by a net present value (NPV) analysis suggesting considerable upside potential. Furthermore, TAEUS technology promises to enhance the diagnostic accuracy and cost-effectiveness for monitoring Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), thereby positioning the company favorably in the healthcare market where effective diagnostic solutions are currently lacking.

Bears say

ENDRA Life Sciences reported a net loss of $1.2 million, translating to an earnings per share (EPS) of $(1.71), which was better than previous estimates of $(2.27). However, the company faces significant risks, including balance sheet and liquidity issues, potential failures in clinical trials, and challenges related to regulatory approvals and commercialization of its products. Additionally, external factors such as competition, macroeconomic conditions, and fluctuations in investor sentiment toward biotech and medtech stocks contribute to the negative outlook on the company's financial prospects.

NDRA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ENDRA Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ENDRA Life Sciences (NDRA) Forecast

Analysts have given NDRA a Strong Buy based on their latest research and market trends.

According to 1 analysts, NDRA has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ENDRA Life Sciences (NDRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.